Suppr超能文献

2019冠状病毒病疫苗接种:儿科人群面临的挑战

COVID-19 vaccination: challenges in the pediatric population.

作者信息

Azoicai Alice Nicoleta, Miron Ingrith, Lupu Ancuta, Alexoae Monica Mihaela, Starcea Iuliana Magdalena, Alecsa Mirabela, Lupu Vasile Valeriu, Danielescu Ciprian, Nedelcu Alin Horatiu, Salaru Delia Lidia, Dragan Felicia, Ioniuc Ileana

机构信息

Pediatrics, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.

Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.

出版信息

Front Public Health. 2025 Jan 29;12:1390951. doi: 10.3389/fpubh.2024.1390951. eCollection 2024.

Abstract

Vaccination is considered to be one of the most effective means of protecting individuals and populations from the risks associated with exposure to various pathogens. The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affected people of all ages worldwide. In response, several pharmaceutical companies rapidly leveraged their resources to develop vaccines within a very short period of time, leading to the introduction of new, improved, and combination vaccines for community-wide immunization. This review aims to provide a summary of the available literature on the efficacy and safety of COVID-19 vaccines in the pediatric population ranging from 0 to 18 years. An analysis of recent published studies reveals that the majority of clinical trials have reported a sustained immune response following COVID-19 vaccination in children across various age groups worldwide. The majority of the authors highlighted the effectiveness and safety of immunization schedules in children and adolescents. The population-level efficacy of this vaccination remains to be determined, provided that the benefits outweigh the potential risks. Long-term side effects must still be monitored to enable the development of safer and more effective vaccines for future pandemics.

摘要

疫苗接种被认为是保护个人和人群免受接触各种病原体相关风险的最有效手段之一。由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的新冠疫情影响了全球所有年龄段的人群。作为回应,几家制药公司迅速利用其资源在很短的时间内开发疫苗,从而推出了用于社区免疫的新型、改良型和联合疫苗。本综述旨在总结关于0至18岁儿童群体中新冠疫苗效力和安全性的现有文献。对近期发表研究的分析表明,大多数临床试验报告称,全球各年龄组儿童接种新冠疫苗后都产生了持续的免疫反应。大多数作者强调了儿童和青少年免疫接种计划的有效性和安全性。只要益处大于潜在风险,这种疫苗接种在人群层面的效力仍有待确定。仍必须监测长期副作用,以便为未来的大流行开发更安全、更有效的疫苗。

相似文献

1
COVID-19 vaccination: challenges in the pediatric population.2019冠状病毒病疫苗接种:儿科人群面临的挑战
Front Public Health. 2025 Jan 29;12:1390951. doi: 10.3389/fpubh.2024.1390951. eCollection 2024.
2
COVID-19 Vaccination in Children: An Open Question.儿童 COVID-19 疫苗接种:一个悬而未决的问题。
Curr Pediatr Rev. 2022;18(3):226-236. doi: 10.2174/1573396318666211220093111.
4
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗:除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
5
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南(2022—2023年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.

本文引用的文献

1
Myocarditis associated with COVID-19 vaccination.与新冠病毒疫苗接种相关的心肌炎
NPJ Vaccines. 2024 Jun 28;9(1):122. doi: 10.1038/s41541-024-00893-1.
3
Overview of U.S. COVID-19 vaccine safety surveillance systems.美国 COVID-19 疫苗安全监测系统概述。
Vaccine. 2024 Sep 17;42 Suppl 3:125748. doi: 10.1016/j.vaccine.2024.02.065. Epub 2024 Apr 16.
8
COVID-19 Vaccines in Children.儿童新冠疫苗
J Clin Med. 2023 Dec 23;13(1):87. doi: 10.3390/jcm13010087.
9
Vaccination against COVID-19 - risks and benefits in children.儿童 COVID-19 疫苗接种 - 风险与获益。
Eur J Pediatr. 2024 Mar;183(3):1107-1112. doi: 10.1007/s00431-023-05380-8. Epub 2024 Jan 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验